STOK Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of 19%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Biogen, Inc.'s return on equity of 9.36%.

Stoke Therapeutics, Inc. has a consensus price target of $34.25, signalling upside risk potential of 4.26%. On the other hand Biogen, Inc. has an analysts' consensus of $191.03 which suggests that it could grow by 1.82%. Given that Stoke Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Biogen, Inc..

Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.301%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 49.78x while Biogen, Inc.'s PE ratio is 17.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 9.32x versus 2.84x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -259.95%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Insmed, Inc.'s return on equity of -193.23%.

Stoke Therapeutics, Inc. has a consensus price target of $34.25, signalling upside risk potential of 4.26%. On the other hand Insmed, Inc. has an analysts' consensus of $214.44 which suggests that it could grow by 21.86%. Given that Insmed, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Insmed, Inc. is more attractive than Stoke Therapeutics, Inc..

Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.523%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Insmed, Inc.'s net income of -$370M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 49.78x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 9.32x versus 74.89x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Mirum Pharmaceuticals, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of 2.18%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Mirum Pharmaceuticals, Inc.'s return on equity of -16.73%.

Stoke Therapeutics, Inc. has a consensus price target of $34.25, signalling upside risk potential of 4.26%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $103.10 which suggests that it could grow by 19.09%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Stoke Therapeutics, Inc..

Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.567%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Mirum Pharmaceuticals, Inc. quarterly revenues of $133M. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Mirum Pharmaceuticals, Inc.'s net income of $2.9M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 49.78x while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 9.32x versus 9.34x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of 21.32%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Pfizer Inc.'s return on equity of 10.84%.

Stoke Therapeutics, Inc. has a consensus price target of $34.25, signalling upside risk potential of 4.26%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 12.47%. Given that Pfizer Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Pfizer Inc. is more attractive than Stoke Therapeutics, Inc..

Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.75% to investors and pays a quarterly dividend of $0.43 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 49.78x while Pfizer Inc.'s PE ratio is 14.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 9.32x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.